Keros Therapeutics, Inc.
KROS
NASDAQ·Healthcare·Biotechnology·Mkt cap $362.2M
$11.32
▲ +1.89%
P/E
-20.21
Mkt Cap
$362.2M
52-Wk Range
$9.69–$22.55
52-Week Range
$9.69 - $22.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 26.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary protein therapeutic platform targeting high unmet medical needs
- Diversified pipeline addressing multiple rare and serious diseases
- Focus on cytopenias and bone loss disorders with limited current treatment options
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical trial progression of KER-050 for myelodysplastic syndromes and myelofibrosis
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+13.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying KROS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 3, 2026
Reported EPS of -$1.45 vs -$1.34 consensus (-8.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-8.2%
Revenue trend · last 8Q
—
—
—
—
+3576%
-87%
-100%
0%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$388.0K
$3.0M
$211.2M
$18.2M
$14.3M
$385.0K
$367.0K
$18.2M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-169.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 4, 2026
vs Industry
How KROS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related